Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Single-Arm, 2-Stage, Open-label, Phase II Trial of Azacitidine in Relapsed and Refractory Multiple Myeloma.

NCT00412919 is registered in ClinicalTrials.gov with Bayside Health as lead sponsor.

NCT NCT00412919
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00412919 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Single-Arm, 2-Stage, Open-label, Phase II Trial of Azacitidine in Relapsed and Refractory Multiple Myeloma.
Lead sponsor
Bayside Health
Phase
Phase 2
Overall status
Terminated
Start date
December 31, 2006
Completion date
November 30, 2008
Enrollment
7 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma